News Formal

Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion

  • 📰 WSJ
  • ⏱ Reading Time:
  • 11 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Johnson & Johnson said it will buy Momenta Pharmaceuticals in a deal that would broaden the position of its Janssen Pharmaceutical Cos. unit in immune-mediated diseases and allow the unit to expand into autoantibody-driven disease

Colin KellaherJohnson & Johnson on Wednesday said it agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion, or $52.50 a share, in cash.

The deal represents a roughly 70% premium to Tuesday’s closing price of $30.81 for Momenta, a Cambridge, Mass., biotechnology company focused on developing treatments of rare immune-mediated diseases.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Lots of M&As are coming...

YUCK! Monopolies are anti-free market & illegal - Sherman Anti-Trust law!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

ICE borrows $6.5 billion to expand its mortgage industry footprintIntercontinental Exchange Inc, the owner of the New York Stock Exchange, on Monday raised more than half of the $11 billion it plans to pay for Ellie Mae, a...
Source: MarketWatch - 🏆 3. / 97 Read more »